Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.

Example Input: Paragraph: Limiting the quantity per dosage unit will reduce the risk of inadvertent overdose, which can lead to liver failure, liver transplant and death, the Food and Drug Administration said. It cited the fact that no available data showed that taking more than the recommended dose provided benefits that outweighed the added risks. (link.reuters.com/nen95v)  Inadvertent overdose from combination drugs containing acetaminophen, also known as paracetamol in most countries outside the United States, accounts for nearly half of all cases of acetaminophen-related liver failure in the United States, the agency said. Combination acetaminophen products are commonly prescribed to patients to treat pain from acute injuries, post-operative pain, or pain following dental procedures. In January 2011, the FDA asked manufacturers of combination drugs containing acetaminophen, sold globally under trade names such as Tylenol and Panadol, to limit acetaminophen doses to no more than 325 mg in each tablet or capsule by January 14, 2014. (link.reuters.com/hyn95v)  Some of these products still remain available, the agency said. The FDA also suggested that pharmacists who receive a prescription for a combination product with more than the recommended dose contact the prescriber to discuss using a lower dose. In the near future, the FDA plans to institute proceedings to withdraw approval for combination drugs that remain on the market, it said in a statement. Acetaminophen, one of the most commonly used drugs in the United States, is widely used in both prescription and over-the-counter products to reduce pain and fever. Claim: FDA asks doctors to limit acetaminophen in combination drugs.
Example Output: U.S. health regulators recommended on Tuesday that healthcare professionals stop prescribing combination drugs that contain more than 325 milligrams of acetaminophen per tablet, capsule, or other dosage unit, citing the risk of liver damage.

Example Input: Paragraph: Pfizer shares were up nearly 4 percent on positive findings for the oral treatment, called palbociclib, one of the company’s most important experimental drugs that some analysts believe could eventually claim annual sales of more than $5 billion, if approved. The trial tested the pill in post-menopausal patients with locally advanced or newly diagnosed breast cancer that had spread to other parts of the body. “We are delighted with the final data,” Pfizer said in a release, adding the company will discuss the successful data on progression-free survival with the U.S. Food and Drug Administration “to determine next steps” for palbociclib. A secondary goal of the study is to determine whether palbociclib can prolong overall survival. But Pfizer spokeswoman Sally Beatty said the company does not yet have such data, because it takes longer periods to follow patients and gauge survival trends. Although Pfizer is conducting two larger late-stage trials of palbociclib, ISI Group analyst Mark Schoenebaum noted the company has previously said it might discuss with the FDA the potential to seek approval of the medicine based upon mid-stage trial data, if the data warranted. Palbociclib, which blocks enzymes known as cyclin-dependent kinases (CDKs) 4 and 6, was taken in combination with a standard treatment called letrozole among women who were estrogen receptor positive - meaning tumors grow in response to estrogen - and HER2-negative, meaning that the HER2 protein is not causing the cancer. Such patients make up about 60 percent of advanced breast cancer cases. Letrozole is the chemical name of Femara, a Novartis AG drug that belongs to a class of treatments called aromatase inhibitors that block production of estrogen. Pfizer on Monday did not present detailed data from the trial results, saying they would be presented at a scientific meeting in San Diego in April. The success of the trial, called Paloma-1, follows highly favorable interim data that Pfizer unveiled in December 2012. At that point in the study, those taking both palbociclib and letrozole went an average of 26.1 months before tumors worsened. That compared with 7.5 months for those taking letrozole, but not palbociclib. The 18.6-month difference was considered statistically significant. Side effects from palbociclib were similar to those previously reported, Pfizer said on Monday. The earlier interim results had shown that patients taking the drug combination experienced anemia, fatigue and neutropenia - a decline in white blood cells called neutrophils that can put patients at higher risk of infection. Palbociclib was designated a “breakthrough” drug by the FDA last April based on initial data from the trial. The FDA grants “breakthrough” status to drugs that may offer substantial improvement over existing treatments for serious or life-threatening diseases. The status helps to speed up the approval process. Pfizer has started two late-stage trials of the drug - Paloma-2 and Paloma-3 - in patients with advanced breast cancer. Paloma-2 will test the same drug combination, palbociclib and letrozole, as an initial treatment for breast cancer. Paloma-3 will evaluate palbociclib in combination with another hormone therapy, fulvestrant, in women whose cancer has progressed after hormonal therapy. The drug, sold under the brand name Faslodex by AstraZeneca Plc, is called an estrogen receptor antagonist. Companies trying to develop treatments similar to palbociclib include Novartis and Eli Lilly & Co. Breast cancer killed more than 508,000 women worldwide in 2011, according to the World Health Organization. Pfizer shares were up 3.7 percent at $31.53 on Monday morning on the New York Stock Exchange. Claim: Pfizer breast cancer drug succeeds in mid-stage trial.
Example Output: Pfizer Inc’s experimental breast cancer drug significantly delayed progression of symptoms in a mid-stage trial, meeting the study’s primary goal and keeping Pfizer in the forefront of a race for a new standard of care for the disease.

Example Input: Paragraph: The Billings Gazette reported Wednesday that the Montana Human Rights Bureau ruled that Yellowstone County unlawfully denied “gender-affirming health care” to Eleanor Andersen Maloney in 2018. The newspaper reports Maloney was a county prosecutor when she was denied a health insurance request for possible elective surgery, although she was still on a waiting list at the time. The newspaper reports the county also sought the return of payments for Maloney’s therapist. Yellowstone County has 30 days to respond. The case will move to a formal hearing if an agreement is not reached. Calls by the newspaper to the county seeking comment Wednesday were not returned. ___ Information from: The Billings Gazette, http://www.billingsgazette.com Claim: Montana county faces transgender discrimination complaint.
Example Output:
A Montana county may have discriminated against one of its own attorneys by denying the transgender woman access to health care.